Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568119 | 0.90 | PARP1 (0.42) | PTGS2KIF11BRD4 | |
| SCHEMBL4568169 | 0.87 | ENPP2 (0.41) | ENPP2PTGER1 | |
| SCHEMBL4568163 | 0.86 | ENPP2 (0.50) | ENPP2PTGER1 | |
| SCHEMBL15998686 | 0.85 | MRGPRX4 (0.40) | ENPP2GPR17PTGER1 | |
| SCHEMBL4568157 | 0.84 | KIF11 (0.42) | PTGS2KIF11BRD4GPR17 | |
| SCHEMBL4568213 | 0.84 | GPR17 (0.46) | PTGS2ENPP2GPR17PTGER1 | |
| SCHEMBL4568591 | 0.84 | ENPP2 (0.42) | ENPP2PTGER1 | |
| SCHEMBL4568592 | 0.82 | ENPP2 (0.39) | ENPP2PTGER1 | |
| SCHEMBL15998667 | 0.80 | HCAR2 (0.36) | ENPP2PTGER1 | |
| SCHEMBL4568165 | 0.79 | GPR17 (0.43) | PTGS2KIF11GPR17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2474530-B1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | PTGS2 257/4885ENPP2 595/4885KIF11 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.